Post-Marketing Safety Profile of Cladribine in Multiple Sclerosis: A Disproportionality Analysis Based on the FDA Adverse Event Reporting System
November 2025
in “
International Journal of Clinical Pharmacy
”
TLDR Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
The study analyzes the post-marketing safety profile of cladribine in multiple sclerosis using the FDA adverse event reporting system. It confirms known risks of cladribine and identifies new potential safety signals, emphasizing the need for ongoing vigilance regarding early acute toxicity.
